Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc., filed a statement of changes in beneficial ownership on September 10, 2026, reporting the sale of common stock executed the prior day under a pre-established trading plan.

Key Highlights

  • Reporting person: Mark Hopman, Chief Commercial Officer of Beta Bionics, Inc. (NASDAQ:BBNX)
  • Shares sold: 36,870 shares of common stock disposed of (transaction code S) on September 9, 2026
  • Sale price: $18.4628 per share, as reported in the filing
  • Remaining holdings: 87,157 shares of common stock beneficially owned directly following the transaction
  • Trading plan: The sale was made pursuant to a Rule 10b5-1 plan adopted on June 10, 2026
  • Filing signature: Signed by Stephen Feider as Attorney-in-Fact on September 10, 2026

Beta Bionics CCO Reports Common Stock Sale Executed Under Pre-Scheduled Plan

According to the filing, Mark Hopman, who serves as Chief Commercial Officer of Beta Bionics, Inc., sold 36,870 shares of the company's common stock on September 9, 2026, at a price of $18.4628 per share. The transaction is classified with code "S," indicating an open-market sale. Beta Bionics, Inc. trades on NASDAQ under the symbol BBNX.

The filing discloses that the sale was executed pursuant to a Rule 10b5-1 plan that Hopman adopted on June 10, 2026. Rule 10b5-1 plans allow corporate insiders to establish pre-scheduled instructions for securities transactions at a time when they are not in possession of material non-public information. The filing notes this by checking the applicable box indicating the transaction was "made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c)."

Following the reported sale, Hopman directly holds 87,157 shares of Beta Bionics common stock, according to the filing. No derivative securities transactions were reported in Table II of the filing. The statement was filed by Stephen Feider as Attorney-in-Fact on Hopman's behalf on September 10, 2026, the date of earliest filing.

What Was Disclosed

Beta Bionics Chief Commercial Officer Mark Hopman reported the disposition of 36,870 shares of common stock at $18.4628 per share on September 9, 2026, under a Rule 10b5-1 plan adopted June 10, 2026, leaving him with 87,157 directly held shares.